FCCC LOGO Faculty Publications
Travis WD , Garg K , Franklin WA , Wistuba II , Sabloff B , Noguchi M , Kakinuma R , Zakowski M , Ginsberg M , Padera R , Jacobson F , Johnson BE , Hirsch F , Brambilla E , Flieder DB , Geisinger KR , Thunnissen F , Kerr K , Yankelevitz D , Franks TJ , Galvin JR , Henderson DW , Nicholson AG , Hasleton PS , Roggli V , Tsao MS , Cappuzzo F , Vazquez M
Bronchioloalveolar carcinoma and lung adenocarcinoma: The clinical importance and research relevance of the 2004 World Health Organization pathologic criteria
Journal of Thoracic Oncology. 2006 Nov;1(9) :S13-S19
PMID: ISI:000242350700004   
Back to previous list
Abstract
Introduction: Advances in the pathology and computed tomography (CT) of lung adenocarcinoma and bronchioloalveolar carcinoma (BAC) have demonstrated important new prognostic features that have led to changes in classification and diagnostic criteria. Methods: The literature and a set of cases were reviewed by a pathology/CT review panel of pathologists and radiologists who met during a November 2004 International Association for the Study of Lung Cancer/American Society of Clinical Oncology consensus workshop in New York. The group addressed the question of whether sufficient data exist to modify the 2004 World Health Organization (WHO) classification of adenocarcinoma and BAC to define a "minimally invasive" adenocarcinoma with BAC. The problems of diffuse and/or multicentric BAC and adenocarcinoma were evaluated. Results: The clinical concept of BAC needs to be reevaluated with careful attention to the new 2004 WHO criteria because of the major clinical implications. Existing data indicate that patients with solitary, small, peripheral BAC have a 100% 5-year survival rate. The favorable prognostic impact of the restrictive criteria for BAC is already being detected in major epidemiologic data sets such as the Surveillance Epidemiology and End-Results registry. Most lung adenocarcinomas, including those with a BAC component, are invasive and consist of a mixture of histologic patterns. Therefore, they are best classified as adenocarcinoma, mixed subtype. This applies not only to adenocarcinomas with a solitary nodule presentation but also to tumors with a diffuse/multinodular pattern. The percentage of BAC versus invasive components in lung adenocarcinomas seems to be prognostically important. However, at the present time, a consensus definition of "minimally invasive" BAC with a favorable prognosis was not recommended by the panel, so the 1999/2004 WHO criteria for BAC remain unchanged. In small biopsy specimens or cytology specimens, recognition of a BAC component is possible. However, it is not possible to exclude an invasive component. The diagnosis of BAC requires thorough histologic sampling of the tumor. Conclusion: Advances in understanding of the pathology and CT features of BAC and adenocarcinoma have led to important changes in diagnostic criteria and classification of BAC and adenocarcinoma. These criteria need to be uniformly applied by pathologists, radiologists, clinicians, and researchers. The 2004 WHO classification of adenocarcinoma is readily applicable to research studies, but attention needs to be placed on the relative proportion of the adenocarcinoma subtypes. Other recently recognized prognostic features such as size of scar, size of invasive component, or pattern of invasion also seem to be important. More work is needed to determine the most important prognostic pathologic features in lung adenocarcinoma.
Notes
ISI Document Delivery No.: 110AM Times Cited: 0 Cited Reference Count: 43 Cited References: *WHO, 1967, HIST TYP LUNG TUM *WHO, 1981, HIST TYP LUNG TUM AKIRA M, 1999, AM J ROENTGENOL, V173, P1623 AOKI T, 2001, RADIOLOGY, V220, P803 BATTAFARANO RJ, 2002, ANN THORAC SURG, V74, P988 CLAYTON F, 1986, CANCER, V57, P1555 COLBY TV, 1995, TUMORS LOWER RESP TR DALY RC, 1991, ANN THORAC SURG, V51, P368 FURAK J, 2003, EUR J CARDIO-THORAC, V23, P818 GOLDSTEIN NS, 1999, AM J CLIN PATHOL, V112, P391 JANNE PA, 2004, LUNG CANCER-J IASLC, V44, P221 KANEKO M, 2000, CANCER S, V89, P2485 KODAMA K, 2001, LUNG CANCER-J IASLC, V33, P17 KOSAKA T, 2004, CANCER RES, V64, P8919 MCELVANEY G, 1989, CHEST, V95, P151 MILLER VA, 2004, J CLIN ONCOL, V22, P1103 MILLER VA, 2005, J CLIN ONCOL, V23, P3288 MIRTCHEVA RM, 2002, CLIN IMAG, V26, P95 NADAV Y, 1998, HISTOPATHOLOGY, V33, P52 NAKAMURA H, 2004, LUNG CANCER-J IASLC, V44, P61 NOGUCHI M, 1995, CANCER, V75, P2844 OHORI NP, 2004, AM J CLIN PATHOL, V122, P44 PAEZ JG, 2004, SCIENCE, V304, P1497 PAO W, 2004, P NATL ACAD SCI USA, V101, P13306 PAO W, 2005, PLOS MED, V2, E17 ROBERTS PF, 2003, J THORAC CARDIOV SUR, V126, P1597 RUSCH VW, 2002, AJCC CANC STAGING MA, P167 SAKURAI H, 2004, AM J SURG PATHOL, V28, P198 SAKURAI H, 2004, ANN THORAC SURG, V78, P1728 SONE S, 2000, BRIT J RADIOL, V73, P137 SUZUKI K, 2000, ANN THORAC SURG, V69, P893 SWENSEN SJ, 2003, RADIOLOGY, V226, P756 TAKASHIMA S, 2002, LUNG CANCER-J IASLC, V36, P175 TAKASHIMA S, 2002, LUNG CANCER-J IASLC, V36, P289 TAKASHIMA S, 2003, RESPIRATION, V70, P36 TERASAKI H, 2003, AM J SURG PATHOL, V27, P937 THOMPSON WH, 2004, RESP CARE, V49, P1349 TRAVIS WD, 1999, HISTOLOGICAL TYPING TRAVIS WD, 2004, PATHOLOGY GENETICS T TRAVIS WD, 2005, J CLIN ONCOL, V23, P3279 YANG ZG, 2001, AM J ROENTGENOL, V176, P1399 YOKOSE T, 2000, LUNG CANCER-J IASLC, V29, P179 ZELL JA, 2005, J CLIN ONCOL, V23, P8396 Suppl. S